STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIRB) announces that the global fourth quarter net sales of OLYSIO® (simeprevir) amounted to 44 MUSD.
The royalty for the third quarter amounted to 31 MSEK (3.4 MEUR). Medivir’s royalties based on sales for the fourth quarter are calculated from the third royalty tier.
Medivir AB (STO:MVIRB) announces that the global fourth quarter net sales of OLYSIO® (simeprevir) amounted to 44 MUSD. The royalty for the third quarter amounted to 31 MSEK (3.4 MEUR). Medivir’s royalties based on sales for the fourth quarter are calculated from the third royalty tier.
